Effect of dopaminephilic agents and cAMP on tyrosine hydroxylase activity.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000201:enzymology; D003994:Bucladesine / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D004347:Drug Interactions; D004876:Ergot Alkaloids / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D013574:Synaptosomes / Q000201:enzymology; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism*
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D004876:Ergot Alkaloids; D011954:Receptors, Dopamine; D003994:Bucladesine; D000242:Cyclic AMP; D014446:Tyrosine 3-Monooxygenase; D001058:Apomorphine; D004298:Dopamine